HFA was informed by Genentech on March 26, 2018,Â thatÂ aÂ total of fiveÂ patient deaths haveÂ occurredÂ whileÂ the patients wereÂ usingÂ HemlibraÂ (emicizumab-kxwh).Â Genentech has little information that they can presently shareÂ about the circumstancesÂ surrounding theÂ most recentÂ patientÂ deaths; however, Genentech could confirm that the patientsÂ had receivedÂ HemlibraÂ as part ofÂ compassionate use andÂ expanded patient access. Genentech has aÂ Medical Communications lineÂ atÂ 1(800)-821-8590Â for patients, concerned community members, and healthcare providersÂ whoÂ seek further information. HFA encourages you to reach out to GenentechÂ and/or to your treating physicianÂ if you have questions or concerns.
On February 22, 2017, HFAÂ sharedÂ about the death of a patient who was a part of the HAVEN 1Â emicizumabÂ trial. Because the otherÂ 4Â deaths have been under expanded patient access, or compassionate use, there has been little communicationÂ availableÂ from Genentech.
HFA recognizes that there has been robust discussion on socialÂ mediaÂ as the community has been made aware of this and other adverse events surroundingÂ Hemlibra. WeÂ will continue to monitor the situation and share informationÂ asÂ weÂ learnÂ more.
UPDATE, 3/28/2018: Genentech Offers Hemlibra Update
Word From Washington